OVID
$2.01
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
Intraday
Recent News
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -700.58% and -45.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Ovid takes another big swing in neuroscience under a new CEO
After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best fast growing penny stocks to buy according to analysts. Earlier on December 22, LifeSci Capital initiated coverage of Ovid Therapeutics with an Outperform rating and set a price target of $4. Additionally, on December 18, Ovid Therapeutics Inc. (NASDAQ:OVID) announced successful Phase 1 results for OV350, […]
Promising Penny Stocks To Watch In December 2025
As the U.S. stock market continues to reach new heights, with major indices like the Dow Jones and S&P 500 setting all-time records, investors are exploring diverse opportunities across various sectors. Penny stocks, often overlooked yet intriguing investment options, represent smaller or newer companies that can offer significant growth potential at lower price points. Despite their somewhat outdated label, these stocks remain relevant for those seeking hidden value in companies with solid...